To include your compound in the COVID-19 Resource Center, submit it here.

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 4/21 cls
Acorda Therapeutics Inc. (NASDAQ:ACOR) RBC Capital Markets Michael Yee Price target Market outperform -5% $27.56
Yee raised his target to $38 from $32 after the U.S. Patent and Trademark Office allowed a patent application on the composition of Acorda's multiple sclerosis drug Ampyra dalfampridine. The claims of the application, No. 11/010,828, relate to

Read the full 802 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE